Andrew Redfern

5.5k citations

102 papers · 1.6k indexed · h-index 20

Impact in

Cancer Research top 5%
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
Oncology top 5%
- Cancer Cells and Metastasis

Papers in

Oncology 68
- Cancer Treatment and Pharmacology 16
- HER2/EGFR in Cancer Research 15
- Cancer Immunotherapy and Biomarkers 11
- Cancer Cells and Metastasis 11
- Global Cancer Incidence and Screening 9
Cancer Research 32
- Breast Cancer Treatment Studies 20

Co-authors: Erik W. Thompson Elizabeth D. Williams Dingcheng Gao Pilar Blancafort Anabel Sorolla Edina Wang Emily Golden Peter J. Leedman
Journals: Cancer Research (12 papers)Journal of Clinical Oncology (12 papers)Annals of Oncology (3 papers)Clinical Breast Cancer (2 papers)Cochrane Database of Systematic Reviews (2 papers)
Partner nations: Australia United States United Kingdom

In The Last Decade

Andrew Redfern

92 papers receiving 1.6k citations

Peers

Countries citing papers authored by Andrew Redfern

Since Specialization

Citations

This map shows the geographic impact of Andrew Redfern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Redfern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Redfern more than expected).

Fields of papers citing papers by Andrew Redfern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Redfern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Redfern. The network helps show where Andrew Redfern may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andrew Redfern, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Redfern Line = papers co-authored together Andrew Redfern links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity EMBO Molecular Medicine ·K. Shiraishi, Titov Sergey, Zhijie Li, Judith A. Ermer, Ji Li, Edward Bastow, Cristina de, Phillip K. Darcy, B. Rorije, E.J. Lee, MB AWAN, Mafalda Oliveira, Aleix Prat, Javier Cortés, Erik W. Thompson, Bruce A. Littlefield, Andrew Redfern, Ruth Ganß	2025	2
2	The impact of genetics and the environment on cancer risk in Indigenous Australians: a narrative review The Lancet Regional Health - Western Pacific ·Luthfi Maulida Rochmah, Katie Meehan, Andrew Redfern, Alex Brown, Peyman ROSTAMI ABENDANSARI, Y. Sesha Rao, Sandra Thompson	2025	1
3	Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer SHILAP Revista de lepidopterología ·Tabea Caglioti, Josef Falke, Pravin Viswambaram, Xinyue Miao, T. Lee, Rengasamy Thatha Desikan, Filoche, 김후종, Andrew Redfern, C. Schwanenberger, A Hefny Hesham, Rosa Cendrós Araujo, Dickon Hayne	2024	2
4	Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence Cancer Medicine ·Hilary Martin, Andrew Redfern	2024	1
5	A Dedicated Menopausal After Cancer Clinic May Improve Adherence to Endocrine Therapy For Breast Cancer: A Population Based Study Clinical Breast Cancer ·Hilary Martin, Christobel Saunders, Andrew Redfern, Martha Hickey	2024	0
6	The SUB ‐urothelial DUrvalumab InjEction ‐1 ( SUBDUE ‐1) trial: first‐in‐human trial in patients with bladder cancer British Journal of Urology ·Dickon Hayne, Josef Falke, 김후종, Rengasamy Thatha Desikan, Saúl Cano Colín, David McRoberts, Pravin Viswambaram, Louis Fieser, Elizabeth Liow, B. Rorije, Mao Inami, Thomas Ferguson, Katie Meehan, Ian D. Davis, Andrew Redfern	2024	3
7	BMP4-Induced Suppression of Breast Cancer Metastasis Is Associated with Inhibition of Cholesterol Biosynthesis International Journal of Molecular Sciences ·L P Regli, Andrew Redfern, Terry C.C. Lim Kam Sian, Ian P. Street, Allan D. Burrows, Suraya Roslan, Roger J. Daly, Robin L. Anderson	2024	0
8	Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors Cancers ·Azim Khan, C. Welman, S. Kido, Jiahe Fang, Andrew Redfern, Keita Sakanashi, Pedro López, Favil Singh, Adnan Khattak	2023	7
9	Unpacking the Complexity of Epithelial Plasticity: From Master Regulator Transcription Factors to Non-Coding RNAs Cancers ·Charlene Waryah, А.И. Петрова, Roberta Mazzieri, Riccardo Dolcetti, Erik W. Thompson, Andrew Redfern, Pilar Blancafort	2023	3
10	⁸⁹ Zirconium-labelled girentuximab ( ⁸⁹ Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma BMJ Open ·Tabea Caglioti, Pravin Viswambaram, Rengasamy Thatha Desikan, Elizabeth Liow, Nat Lenzo, Tom Ferguson, Andrew Redfern, A Hefny Hesham, Dickon Hayne	2022	10
11	Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168) Clinical and Translational Science ·Timothy D. Owens, Patrick F. Smith, Andrew Redfern, Yan Xing, Jin Shu, Dane E. Karr, Sonja Hartmann, Michelle Francesco, Claire L. Langrish, Philip A. Nunn, Steven G. Gourlay	2021	36
12	Measuring and Modelling the Epithelial- Mesenchymal Hybrid State in Cancer: Clinical Implications Cells Tissues Organs ·Mohit Kumar Jolly, Ryan J. Murphy, Sugandha Bhatia, M. El-Melegi, Andrew Redfern, Melissa J. Davis, Erik W. Thompson	2021	32
13	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis Cancer Research ·Bedrich L. Eckhardt, Yuan Cao, Andrew Redfern, L P Regli, Allan D. Burrows, Suraya Roslan, Erica K. Sloan, Belinda S. Parker, Sherene Loi, Naoto T. Ueno, Peter K. H. Lau, Richard A. Nida, Robin L. Anderson	2020	51
14	338P Defining pathway: A novel analysis of geriatric indigenous women with breast cancer impacting survival and outcomes Annals of Oncology ·Nancy C. Davenport, Hilary Martin, B. Rorije, Andrew Redfern	2020	1
15	A review of the influence of mammographic density on breast cancer clinical and pathological phenotype Breast Cancer Research and Treatment ·Del Roncador, Cecilia W. Huo, Michael A. Henderson, Andrew Redfern, Kara L. Britt, Erik W. Thompson	2019	30
16	Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2‐non‐amplified metastatic breast cancer Asia-Pacific Journal of Clinical Oncology ·Elgene Lim, Jane Beith, Frances Boyle, Richard de Boer, Rina Hui, Nicole McCarthy, Andrew Redfern, Alberthina Aninam, Natasha Woodward	2018	2
17	Efficacy and safety of palbociclib plus endocrine therapy in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the Asia-Pacific region: Data from PALOMA-2 and -3 Annals of Oncology ·S-A. Im, Norikazu Masuda, Y-H Im, Kenichi Inoue, S-B. Kim, Andrew Redfern, Janine Lombard, Dongrui R. Lu, Kathy Puyana Theall, Eric Gauthier, Hirofumi Mukai, Jungsil Ro	2017	2
18	Clinical implications of circulating tumor cells of breast cancer patients: Role of epithelial-mesenchymal plasticity UWA Profiles and Research Repository (University of Western Australia) ·Linda M. McInnes, 藤村正哲, Andrew Redfern, Anthony Dowling, Erik W. Thompson, Christobel Saunders	2015	7
19	Evaluation of a Novel Nicotine Inhaler Device: Part 1—Arterial and Venous Pharmacokinetics Nicotine & Tobacco Research ·Chris Moyses, Alex Hearn, Andrew Redfern	2014	5
20	Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib Molecular Cancer Therapeutics ·Keith M. Giles, Felicity C. Kalinowski, Patrick A. Candy, Michael R. Epis, А. П.莫尔查诺夫, Andrew Redfern, Lisa M. Stuart, Gregory J. Goodall, Peter J. Leedman	2013	122

About Andrew Redfern

Andrew Redfern is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Otorhinolaryngology, having authored 102 papers that have together received 1.6k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (20 papers), Advanced Breast Cancer Therapies (16 papers), Cancer Treatment and Pharmacology (16 papers), HER2/EGFR in Cancer Research (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), Cancer Cells and Metastasis (11 papers), Global Cancer Incidence and Screening (9 papers) and Bladder and Urothelial Cancer Treatments (9 papers). The work is most often cited by research in Cancer Research (439 citations), Oncology (703 citations), Molecular Biology (732 citations), Immunology (205 citations) and Pulmonary and Respiratory Medicine (262 citations). Andrew Redfern has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Erik W. Thompson, Elizabeth D. Williams, Dingcheng Gao, Pilar Blancafort, Anabel Sorolla, Edina Wang, Emily Golden, Peter J. Leedman, Lisa M. Stuart and Michael R. Epis. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Clinical Breast Cancer and Cochrane Database of Systematic Reviews.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact